United Therapeutics - UTHR Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 2 sell ratings, 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" UTHR shares.
View UTHR analyst ratings or view top-rated stocks.

11 brokerages have issued 1 year target prices for United Therapeutics' stock. Their UTHR share price forecasts range from $203.00 to $375.00. On average, they anticipate the company's share price to reach $282.00 in the next twelve months. This suggests a possible upside of 0.8% from the stock's current price.
View analysts price targets for UTHR or view top-rated stocks among Wall Street analysts.

United Therapeutics' stock was trading at $216.08 at the beginning of 2022. Since then, UTHR stock has increased by 29.5% and is now trading at $279.88.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our UTHR earnings forecast.

United Therapeutics Co. (NASDAQ:UTHR) announced its earnings results on Wednesday, November, 2nd. The biotechnology company reported $4.91 earnings per share for the quarter, beating the consensus estimate of $3.57 by $1.34. The biotechnology company earned $516 million during the quarter, compared to analysts' expectations of $492.92 million. United Therapeutics had a trailing twelve-month return on equity of 16.63% and a net margin of 38.03%.

64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

United Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.68%), BlackRock Inc. (9.49%), Renaissance Technologies LLC (5.60%), State Street Corp (3.50%), Palo Alto Investors LP (1.39%) and Assenagon Asset Management S.A. (1.35%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon, Raymond Dwek, Richard Giltner and Tommy G Thompson.
View institutional ownership trends.

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of UTHR stock can currently be purchased for approximately $279.88.

United Therapeutics (NASDAQ:UTHR) has a market capitalization of $12.76 billion and generates $1.69 billion in revenue each year. The biotechnology company earns $475.80 million in net income (profit) each year or $14.70 on an earnings per share basis.

The company employs 965 workers across the globe.

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The official website for the company is www.unither.com. The biotechnology company can be reached via phone at (301) 608-9292, via email at ir@unither.com, or via fax at 301-608-9291.